NCT02650401: Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

NCT02650401
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, ALK, ROS
Breast Cancer Tissue: Secretory Breast Cancer
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 22 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patients with solid tumors with or without NTRK, ROS, or ALK fusions are eligible
Exclusions: Patients over the age of 22
https://ClinicalTrials.gov/show/NCT02650401

Comments are closed.

Up ↑